SARM1 and early-onset autosomal dominant Alzheimer disease: This degeneration requires both the MAP3K Wnd/DLK and the NADase SARM1, both of which are well-known neurodegenerative actors linked to a range of central and peripheral nervous system diseases, such as chemotherapy-induced peripheral neuropathy (CIPN), ALS, and Alzheimer’s disease [39,[112], [113], [114], [115], [116], [117], [118], [119], [120], [121], [122], [123], [124]].